Sofosbuvir and velpatasvir (Epclusa) cure rates

The sofosbuvir-velpatasvir (Epclusa) combination can cure hepatitis C virus (HCV) in many patients and has an overall cure rate of 98% for all six major types of hepatitis C in patients without cirrhosis (a severe form of liver disease) or compensated cirrhosis (mild or asymptomatic). "Cure" means no HCV is detectable in the blood three months after completion of treatment. With virological response (SVR), the virus is no longer detectable and 80% to 100% of patients can be cured, sometimes with just 8 to 12 weeks of treatment. However, drug resistance can develop; two or more oral HCV drugs will be used together to help prevent drug resistance.